Stock Events

Stock Events

Biomea Fusion 

$1.54
52
+$0.05+3.36% Thursday 20:00

Statistics

Day High
1.54
Day Low
1.39
52W High
3.08
52W Low
0.87
Volume
1,181,202
Avg. Volume
1,231,960
Mkt Cap
108.88M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q1 2024
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Next
-1.09
-0.8
-0.52
-0.23
Expected EPS
-0.233582
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-276.85MNet Income

Analyst Ratings

$9.50Average Price Target
The highest estimate is 12.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BMEA. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of biotechnology that could compete with Biomea Fusion's focus on innovative treatments for diseases.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the gene editing space, directly competing with Biomea Fusion's efforts in developing novel therapeutics.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing technology, posing competition to Biomea Fusion's therapeutic development strategies.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics uses base editing technology, a form of gene editing, which competes with Biomea Fusion's approach to developing unique treatments.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics focuses on genomic medicine, including gene therapy and gene editing, competing with Biomea Fusion's innovative treatment methodologies.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, a novel approach that could compete with Biomea Fusion's drug development pipeline.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals is a leader in RNA-targeted drug discovery and development, competing with Biomea Fusion's focus on innovative therapeutic solutions.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is involved in creating transformative medicines for serious diseases, potentially competing with Biomea Fusion's target disease areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is known for its innovation in biopharmaceuticals, which could compete with Biomea Fusion's efforts in developing novel treatments for diseases.

About

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Show more...
CEO
Dr. Michael J. M. Hitchcock Ph.D.
Employees
79
Country
US
ISIN
US09077A1060

Listings

XNAS
US
BMEA
BOATS
BOATS
BMEA.BOATS

0 Comments

Share your thoughts

FAQ

What is Biomea Fusion stock price today?▼
The current price of BMEA is $1.54 USD — it has increased by +3.36% in the past 24 hours. Watch Biomea Fusion stock price performance more closely on the chart.
What is Biomea Fusion stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Biomea Fusion stocks are traded under the ticker BMEA.
Is Biomea Fusion stock price growing?▼
BMEA stock has risen by +16.67% compared to the previous week, the month change is a +10.79% rise, over the last year Biomea Fusion has showed a -27.36% decrease.
What is Biomea Fusion market cap?▼
Today Biomea Fusion has the market capitalization of 108.88M
When is the next Biomea Fusion earnings date?▼
Biomea Fusion is going to release the next earnings report on May 06, 2026.
What were Biomea Fusion earnings last quarter?▼
BMEA earnings for the last quarter are -0.27 USD per share, whereas the estimation was -0.26 USD resulting in a -5.37% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Biomea Fusion revenue for the last year?▼
Biomea Fusion revenue for the last year amounts to 0 USD.
What is Biomea Fusion net income for the last year?▼
BMEA net income for the last year is -276.85M USD.
How many employees does Biomea Fusion have?▼
As of April 04, 2026, the company has 79 employees.
In which sector is Biomea Fusion located?▼
Biomea Fusion operates in the Health Care sector.
When did Biomea Fusion complete a stock split?▼
Biomea Fusion has not had any recent stock splits.
Where is Biomea Fusion headquartered?▼
Biomea Fusion is headquartered in San Carlos, US.